User login
Carvedilol superior to metoprolol for preventing death from CHF
Among white patients with symptomatic systolic dysfunction on stable treatment with diuretics and angiotensin-converting enzyme (ACE) inhibitors, the addition of the nonselective beta-blocker carvedilol extends survival by 17% per year compared with metoprolol. This benefit translates into a number needed to treat (NNT) of 17 for 5 years. This extrapolates to an added 1.4 years of life.
It is unclear whether this benefit holds true for nonwhite patients. Carvedilol should be considered over metoprolol for treating patients with congestive heart failure to improve survival.
Among white patients with symptomatic systolic dysfunction on stable treatment with diuretics and angiotensin-converting enzyme (ACE) inhibitors, the addition of the nonselective beta-blocker carvedilol extends survival by 17% per year compared with metoprolol. This benefit translates into a number needed to treat (NNT) of 17 for 5 years. This extrapolates to an added 1.4 years of life.
It is unclear whether this benefit holds true for nonwhite patients. Carvedilol should be considered over metoprolol for treating patients with congestive heart failure to improve survival.
Among white patients with symptomatic systolic dysfunction on stable treatment with diuretics and angiotensin-converting enzyme (ACE) inhibitors, the addition of the nonselective beta-blocker carvedilol extends survival by 17% per year compared with metoprolol. This benefit translates into a number needed to treat (NNT) of 17 for 5 years. This extrapolates to an added 1.4 years of life.
It is unclear whether this benefit holds true for nonwhite patients. Carvedilol should be considered over metoprolol for treating patients with congestive heart failure to improve survival.